<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PMJ</journal-id>
<journal-id journal-id-type="hwp">sppmj</journal-id>
<journal-id journal-id-type="nlm-ta">Palliat Med</journal-id>
<journal-title>Palliative Medicine</journal-title>
<issn pub-type="ppub">0269-2163</issn>
<issn pub-type="epub">1477-030X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269216311419882</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269216311419882</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evidence for orthopaedic surgery in the treatment of metastatic bone disease of the extremities: A review article</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Malviya</surname><given-names>Ajay</given-names></name>
<aff id="aff1-0269216311419882">Freeman Hospital, Newcastle upon Tyne, UK</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Gerrand</surname><given-names>Craig</given-names></name>
<aff id="aff2-0269216311419882">Freeman Hospital, Newcastle upon Tyne, UK</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0269216311419882">A Malviya, 81 Daylesford Drive, Gosforth, Newcastle upon Tyne, NE3 1TW, UK. Email: <email>amalviya@nhs.net</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>26</volume>
<issue>6</issue>
<fpage>788</fpage>
<lpage>796</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-0269216311419882">
<title>Background:</title>
<p>The decision to offer orthopaedic surgery to patients with metastatic bone disease is often difficult and requires an understanding of the underlying disease, the patient’s needs or wishes, the expected outcomes and the principles of surgery.</p>
</sec>
<sec id="section2-0269216311419882">
<title>Aim:</title>
<p>We aimed to look at the literature to support the role of orthopaedic surgery for skeletal metastasis in improving key outcomes such as pain, quality of life and physical functioning.</p>
</sec>
<sec id="section3-0269216311419882">
<title>Design:</title>
<p>Review article.</p>
</sec>
<sec id="section4-0269216311419882">
<title>Data sources:</title>
<p>The ‘Dialog Datastar’ database was used to access Medline and other resources from 1951 to December 2009 using keywords ‘Metasta$’ AND ‘Bone or Skeletal’ AND ‘Results Or Outcome Or Surg$ Or Management’.</p>
</sec>
<sec id="section5-0269216311419882">
<title>Results:</title>
<p>The majority of the studies that have looked at these key outcomes are limited by their design and their use of non-validated outcome measures. This study has detailed the measures to assess outcome, predict survival, predict fracture and how to arrive at key decisions, such as when to operate and when not to operate on these patients.</p>
</sec>
<sec id="section6-0269216311419882">
<title>Conclusion:</title>
<p>Timely and appropriate surgical intervention reliably alleviates pain and improves quality of life and can be undertaken with few complications in most patients. Although most procedures can be undertaken by non-specialists, consultation with other members of the multidisciplinary team is mandatory, and in complex cases, referral to a specialist orthopaedic oncology centre can be helpful.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Bone and bones</kwd>
<kwd>neoplasm metastasis</kwd>
<kwd>operative procedures</kwd>
<kwd>quality of life</kwd>
<kwd>treatment outcome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section7-0269216311419882" sec-type="intro">
<title>Introduction</title>
<p>Metastatic bone disease of the extremities is the most common cause of bone destruction in the palliative care setting. Although bone can also be involved by haemopoietic malignancies, such as myeloma or local invasion by non-bone malignancy,<sup><xref ref-type="bibr" rid="bibr1-0269216311419882">1</xref>,<xref ref-type="bibr" rid="bibr2-0269216311419882">2</xref></sup> these are less common and primary bone sarcomas are rare. The clinical presentation of patients with metastatic bone disease varies, but can include pathological fracture, bone pain and radiological abnormalities. Pathological fracture is usually a devastating event, associated with significant pain and disability, and yet half of the patients with a fracture will survive six months or more.<sup><xref ref-type="bibr" rid="bibr3-0269216311419882">3</xref>,<xref ref-type="bibr" rid="bibr4-0269216311419882">4</xref></sup> Appropriate treatment of metastatic bone disease is therefore an important part of the management of many patients in the palliative care setting.<sup><xref ref-type="bibr" rid="bibr5-0269216311419882">5</xref></sup> The aim of treatment is to relieve pain, and to preserve or improve quality of life (QoL) and physical function while minimizing the risk of complications. In some cases, the appropriate treatment of bony metastases may improve survival.<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref><xref ref-type="bibr" rid="bibr7-0269216311419882"/><xref ref-type="bibr" rid="bibr8-0269216311419882"/>–<xref ref-type="bibr" rid="bibr9-0269216311419882">9</xref></sup></p>
<p>Appropriate and timely orthopaedic surgery has a great deal to offer patients with metastatic bone disease, within the context of a multidisciplinary team approach, which remains the standard for care.<sup><xref ref-type="bibr" rid="bibr10-0269216311419882">10</xref>,<xref ref-type="bibr" rid="bibr11-0269216311419882">11</xref></sup> A team approach ensures that the patient can be offered appropriate conservative treatment options, such as radiotherapy, before surgical intervention. Despite this, the decision to offer orthopaedic surgery to patients with metastatic bone disease is often difficult and requires consideration of predicted survival, the general health of the patient, the expected response to adjuvant treatment, reconstructability of the bone in question, whether or not the bone is weight bearing and the effect of the metastasis on physical function.<sup><xref ref-type="bibr" rid="bibr12-0269216311419882">12</xref></sup> A particular difficulty arises when considering prophylactic fixation of a bony metastasis given that, despite the availability of systems to predict the risk of fracture and survival,<sup><xref ref-type="bibr" rid="bibr13-0269216311419882">13</xref></sup> considerable uncertainty remains.</p>
<p>The goals of surgery are to achieve local tumour control and structural stability to restore function as quickly as possible.<sup><xref ref-type="bibr" rid="bibr5-0269216311419882">5</xref>,<xref ref-type="bibr" rid="bibr14-0269216311419882">14</xref></sup> Ideally, operative treatment should allow immediate weight bearing with the least possible morbidity.<sup><xref ref-type="bibr" rid="bibr5-0269216311419882">5</xref>,<xref ref-type="bibr" rid="bibr14-0269216311419882">14</xref></sup> Surgical techniques to address bony metastases in the appendicular skeleton include internal fixation, sometimes augmented with methylmethacrylate bone cement and endoprosthetic replacement. Surgery is often associated with prolonged stays in hospital and the use of significant resources, although this can be cost effective,<sup><xref ref-type="bibr" rid="bibr15-0269216311419882">15</xref></sup> particularly when the patient continues to live independently as a result of surgical intervention. Preoperative tumour embolization can be helpful in the management of vascular tumours, such as metastases from renal cancer.</p>
<p>Given the complexity of decision making in this clinical situation, it is important to ensure that decisions are supported by the literature. The aim of this review article is to examine the literature pertaining to the surgical management of metastatic bone disease of the extremities to identify how effective orthopaedic surgery is in improving symptoms, QoL and physical functioning.</p>
</sec>
<sec id="section8-0269216311419882" sec-type="methods">
<title>Methods</title>
<p>The ‘Dialog Datastar’ database was used to access Medline (1951–December 2008), Allied &amp; Complementary Medicine (1985–December 2008), British Nursing Index (1994–December 2008), CINAHL (1982–December 2008), DH-DATA (1983–December 2008), EMBASE (1974–December 2008), King’s Fund (1979–December 2008) and PsycINFO (1806–December 2008). The keywords used were ‘Metasta$’ AND ‘Bone or Skeletal’ AND ‘Results Or Outcome Or Surg$ Or Management’. A further Pubmed search was performed for articles between January 2009 and December 2009. We included only the articles published in English language. Preliminary screening of the abstracts of the articles (225) was performed and, after excluding the clearly irrelevant papers, 130 full text articles were obtained. We excluded articles looking at non- surgical management (radiotherapy or pharmacological intervention); articles on spinal, pelvic, rib cage, clavicle or skull metastasis; and also review articles or personal opinion (Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram). The articles on surgical management of the appendicular skeleton were shortlisted and a further hand search was done of the relevant references of these articles to avoid any articles that might have been missed on the initial search. A total of 64 articles have been included in this review.</p>
<p>We have not performed a formal assessment for the risk of bias that may affect cumulative evidence, as we have not attempted to perform a meta-analysis, but have mentioned in the results where they may be a potential risk of selection bias in the studies. We recorded data on the number of subjects included, primary diagnosis, anatomic site, follow-up, survival, outcome measures used, impact on QoL, functional outcome, pain relief, type of intervention, use of bone cement, complications and level of evidence.</p>
</sec>
<sec id="section9-0269216311419882" sec-type="results">
<title>Results</title>
<p>These articles were further explored for the following.</p>
<list id="list1-0269216311419882" list-type="order">
<list-item><p>Does orthopaedic surgery relieve pain?</p></list-item>
<list-item><p>The impact of orthopaedic surgery on QoL and physical functioning.</p></list-item>
<list-item><p>Will patients live long enough to benefit? Predicting survival.</p></list-item>
<list-item><p>Predicting a fracture.</p></list-item>
<list-item><p>When to operate?</p></list-item>
<list-item><p>When not to operate?</p></list-item>
<list-item><p>Complications of surgery.</p></list-item>
</list>
<sec id="section10-0269216311419882">
<title>Does orthopaedic surgery relieve pain?</title>
<p>Although pain relief is the primary goal of the treatment of bone metastases, not all studies include pain assessments.<sup><xref ref-type="bibr" rid="bibr16-0269216311419882">16</xref><xref ref-type="bibr" rid="bibr17-0269216311419882"/><xref ref-type="bibr" rid="bibr18-0269216311419882"/><xref ref-type="bibr" rid="bibr19-0269216311419882"/><xref ref-type="bibr" rid="bibr20-0269216311419882"/><xref ref-type="bibr" rid="bibr21-0269216311419882"/><xref ref-type="bibr" rid="bibr22-0269216311419882"/><xref ref-type="bibr" rid="bibr23-0269216311419882"/><xref ref-type="bibr" rid="bibr24-0269216311419882"/>–<xref ref-type="bibr" rid="bibr25-0269216311419882">25</xref></sup> Those that do use a variety of measures, including non-validated instruments,<sup><xref ref-type="bibr" rid="bibr18-0269216311419882">18</xref>,<xref ref-type="bibr" rid="bibr26-0269216311419882">26</xref><xref ref-type="bibr" rid="bibr27-0269216311419882"/><xref ref-type="bibr" rid="bibr28-0269216311419882"/><xref ref-type="bibr" rid="bibr29-0269216311419882"/><xref ref-type="bibr" rid="bibr30-0269216311419882"/><xref ref-type="bibr" rid="bibr31-0269216311419882"/><xref ref-type="bibr" rid="bibr32-0269216311419882"/><xref ref-type="bibr" rid="bibr33-0269216311419882"/><xref ref-type="bibr" rid="bibr34-0269216311419882"/><xref ref-type="bibr" rid="bibr35-0269216311419882"/><xref ref-type="bibr" rid="bibr36-0269216311419882"/><xref ref-type="bibr" rid="bibr37-0269216311419882"/><xref ref-type="bibr" rid="bibr38-0269216311419882"/><xref ref-type="bibr" rid="bibr39-0269216311419882"/><xref ref-type="bibr" rid="bibr40-0269216311419882"/><xref ref-type="bibr" rid="bibr41-0269216311419882"/><xref ref-type="bibr" rid="bibr42-0269216311419882"/><xref ref-type="bibr" rid="bibr43-0269216311419882"/>–<xref ref-type="bibr" rid="bibr44-0269216311419882">44</xref></sup> subjective measures,<sup><xref ref-type="bibr" rid="bibr45-0269216311419882">45</xref><xref ref-type="bibr" rid="bibr46-0269216311419882"/><xref ref-type="bibr" rid="bibr47-0269216311419882"/><xref ref-type="bibr" rid="bibr48-0269216311419882"/>–<xref ref-type="bibr" rid="bibr49-0269216311419882">49</xref></sup> objective measures (e.g. analgesic use),<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr45-0269216311419882">45</xref>,<xref ref-type="bibr" rid="bibr46-0269216311419882">46</xref>,<xref ref-type="bibr" rid="bibr49-0269216311419882">49</xref><xref ref-type="bibr" rid="bibr50-0269216311419882"/><xref ref-type="bibr" rid="bibr51-0269216311419882"/><xref ref-type="bibr" rid="bibr52-0269216311419882"/><xref ref-type="bibr" rid="bibr53-0269216311419882"/><xref ref-type="bibr" rid="bibr54-0269216311419882"/><xref ref-type="bibr" rid="bibr55-0269216311419882"/>–<xref ref-type="bibr" rid="bibr56-0269216311419882">56</xref></sup> the pain domain of the Musculoskeletal Tumour Society (MSTS) score,<sup><xref ref-type="bibr" rid="bibr16-0269216311419882">16</xref>,<xref ref-type="bibr" rid="bibr57-0269216311419882">57</xref><xref ref-type="bibr" rid="bibr58-0269216311419882"/><xref ref-type="bibr" rid="bibr59-0269216311419882"/><xref ref-type="bibr" rid="bibr60-0269216311419882"/><xref ref-type="bibr" rid="bibr61-0269216311419882"/><xref ref-type="bibr" rid="bibr62-0269216311419882"/>–<xref ref-type="bibr" rid="bibr63-0269216311419882">63</xref></sup> or the formal pain scores in the Aboulafia<sup><xref ref-type="bibr" rid="bibr50-0269216311419882">50</xref>,<xref ref-type="bibr" rid="bibr51-0269216311419882">51</xref>,<xref ref-type="bibr" rid="bibr58-0269216311419882">58</xref></sup> and Allan systems.<sup><xref ref-type="bibr" rid="bibr62-0269216311419882">62</xref>,<xref ref-type="bibr" rid="bibr64-0269216311419882">64</xref></sup> Whatever the measure, however, there is widespread agreement that surgical treatment of skeletal metastases leads to pain relief in the majority, if not all, patients<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr18-0269216311419882">18</xref>,<xref ref-type="bibr" rid="bibr26-0269216311419882">26</xref><xref ref-type="bibr" rid="bibr27-0269216311419882"/><xref ref-type="bibr" rid="bibr28-0269216311419882"/><xref ref-type="bibr" rid="bibr29-0269216311419882"/><xref ref-type="bibr" rid="bibr30-0269216311419882"/><xref ref-type="bibr" rid="bibr31-0269216311419882"/><xref ref-type="bibr" rid="bibr32-0269216311419882"/><xref ref-type="bibr" rid="bibr33-0269216311419882"/><xref ref-type="bibr" rid="bibr34-0269216311419882"/><xref ref-type="bibr" rid="bibr35-0269216311419882"/><xref ref-type="bibr" rid="bibr36-0269216311419882"/><xref ref-type="bibr" rid="bibr37-0269216311419882"/><xref ref-type="bibr" rid="bibr38-0269216311419882"/><xref ref-type="bibr" rid="bibr39-0269216311419882"/><xref ref-type="bibr" rid="bibr40-0269216311419882"/><xref ref-type="bibr" rid="bibr41-0269216311419882"/><xref ref-type="bibr" rid="bibr42-0269216311419882"/><xref ref-type="bibr" rid="bibr43-0269216311419882"/><xref ref-type="bibr" rid="bibr44-0269216311419882"/><xref ref-type="bibr" rid="bibr45-0269216311419882"/><xref ref-type="bibr" rid="bibr46-0269216311419882"/><xref ref-type="bibr" rid="bibr47-0269216311419882"/><xref ref-type="bibr" rid="bibr48-0269216311419882"/>–<xref ref-type="bibr" rid="bibr49-0269216311419882">49</xref>,<xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref><xref ref-type="bibr" rid="bibr53-0269216311419882"/><xref ref-type="bibr" rid="bibr54-0269216311419882"/><xref ref-type="bibr" rid="bibr55-0269216311419882"/>–<xref ref-type="bibr" rid="bibr56-0269216311419882">56</xref>,<xref ref-type="bibr" rid="bibr58-0269216311419882">58</xref>,<xref ref-type="bibr" rid="bibr62-0269216311419882">62</xref>,<xref ref-type="bibr" rid="bibr65-0269216311419882">65</xref></sup> (level of evidence III<sup><xref ref-type="bibr" rid="bibr44-0269216311419882">44</xref>,<xref ref-type="bibr" rid="bibr47-0269216311419882">47</xref></sup> and IV).</p>
<p>There is evidence that surgery can offer better pain relief than conservative management. In one retrospective study<sup><xref ref-type="bibr" rid="bibr47-0269216311419882">47</xref></sup> over 80% of patients treated surgically reported satisfactory (excellent to good) pain relief, compared with 45%–60% of those treated conservatively. In another study of 60 patients,<sup><xref ref-type="bibr" rid="bibr44-0269216311419882">44</xref></sup> pain was relieved in 91% of those treated surgically compared with 59% of those treated with radiation and 45% of those treated by other means. Postoperative pain relief may be better in patients undergoing prophylactic fixation of skeletal metastases compared with those treated after pathological fracture (100% versus 70% good-to-excellent pain relief)<sup><xref ref-type="bibr" rid="bibr48-0269216311419882">48</xref></sup> and may be improved by using methylmethacrylate to supplement the fixation of femoral metastases (97% versus 83%).<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref></sup></p>
</sec>
<sec id="section11-0269216311419882">
<title>The impact of orthopaedic surgery on quality of life and physical functioning</title>
<p>Measures used to assess QoL and physical functioning of patients with skeletal metastases include global QoL measures (e.g. SF-36), general performance/disability measures (e.g. Eastern Cooperative Oncology Group (ECOG), Karnofsky), combination measures (e.g. MSTS) and physical functioning measures (e.g. Toronto Extremity Salvage Score (TESS)). Compared with studies of non-surgical interventions, surgical studies more often use non-validated tools for the assessment of patient function.<sup><xref ref-type="bibr" rid="bibr66-0269216311419882">66</xref></sup></p>
<p>The SF-36 assessment has had limited use in this group of patients, with only one study reporting a significant improvement in the SF-36 bodily pain score following surgery, but no improvement in the overall score.<sup><xref ref-type="bibr" rid="bibr60-0269216311419882">60</xref></sup> The ECOG performance status is a commonly used measure of the overall functional status of patients with all types of cancer. The tool has been validated, has good inter-observer and intra-observer reliability<sup><xref ref-type="bibr" rid="bibr67-0269216311419882">67</xref><xref ref-type="bibr" rid="bibr68-0269216311419882"/>–<xref ref-type="bibr" rid="bibr69-0269216311419882">69</xref></sup> and has been incorporated as part of a scoring system to predict outcome following surgery.<sup><xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref></sup> Improvements in ECOG scores have been demonstrated in 67% of 107 patients undergoing orthopaedic surgery for breast cancer metastases in bone,<sup><xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref></sup> and in patients undergoing acetabular reconstruction.<sup><xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref></sup></p>
<p>The Karnofsky Performance Scale Index<sup><xref ref-type="bibr" rid="bibr71-0269216311419882">71</xref></sup> scores functional impairment, and its validity and reliability has been widely tested in a variety of cancers.<sup><xref ref-type="bibr" rid="bibr72-0269216311419882">72</xref></sup> Although the applicability of this measure to this group of patients has not been formally tested, significant improvements in the Karnofsky performance status have been demonstrated in patients with pelvic metastases following surgery<sup><xref ref-type="bibr" rid="bibr73-0269216311419882">73</xref></sup> and it has been used to predict survival.<sup><xref ref-type="bibr" rid="bibr53-0269216311419882">53</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref></sup></p>
<p>Physical function after surgery is often not reported<sup><xref ref-type="bibr" rid="bibr17-0269216311419882">17</xref>,<xref ref-type="bibr" rid="bibr20-0269216311419882">20</xref>,<xref ref-type="bibr" rid="bibr25-0269216311419882">25</xref>,<xref ref-type="bibr" rid="bibr75-0269216311419882">75</xref></sup> or is assessed using non-standard measures. <sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr18-0269216311419882">18</xref>,<xref ref-type="bibr" rid="bibr19-0269216311419882">19</xref>,<xref ref-type="bibr" rid="bibr23-0269216311419882">23</xref>,<xref ref-type="bibr" rid="bibr26-0269216311419882">26</xref><xref ref-type="bibr" rid="bibr27-0269216311419882"/><xref ref-type="bibr" rid="bibr28-0269216311419882"/>–<xref ref-type="bibr" rid="bibr29-0269216311419882">29</xref>,<xref ref-type="bibr" rid="bibr31-0269216311419882">31</xref><xref ref-type="bibr" rid="bibr32-0269216311419882"/><xref ref-type="bibr" rid="bibr33-0269216311419882"/><xref ref-type="bibr" rid="bibr34-0269216311419882"/>–<xref ref-type="bibr" rid="bibr35-0269216311419882">35</xref>,<xref ref-type="bibr" rid="bibr37-0269216311419882">37</xref><xref ref-type="bibr" rid="bibr38-0269216311419882"/><xref ref-type="bibr" rid="bibr39-0269216311419882"/>–<xref ref-type="bibr" rid="bibr40-0269216311419882">40</xref>,<xref ref-type="bibr" rid="bibr42-0269216311419882">42</xref><xref ref-type="bibr" rid="bibr43-0269216311419882"/>–<xref ref-type="bibr" rid="bibr44-0269216311419882">44</xref>,<xref ref-type="bibr" rid="bibr65-0269216311419882">65</xref></sup> Assessments include simple descriptions of ambulatory status for tumours in the lower extremity<sup><xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr21-0269216311419882">21</xref>,<xref ref-type="bibr" rid="bibr22-0269216311419882">22</xref>,<xref ref-type="bibr" rid="bibr30-0269216311419882">30</xref>,<xref ref-type="bibr" rid="bibr35-0269216311419882">35</xref>,<xref ref-type="bibr" rid="bibr36-0269216311419882">36</xref>,<xref ref-type="bibr" rid="bibr41-0269216311419882">41</xref>,<xref ref-type="bibr" rid="bibr46-0269216311419882">46</xref><xref ref-type="bibr" rid="bibr47-0269216311419882"/><xref ref-type="bibr" rid="bibr48-0269216311419882"/>–<xref ref-type="bibr" rid="bibr49-0269216311419882">49</xref>,<xref ref-type="bibr" rid="bibr54-0269216311419882">54</xref>,<xref ref-type="bibr" rid="bibr56-0269216311419882">56</xref>,<xref ref-type="bibr" rid="bibr76-0269216311419882">76</xref></sup> and descriptions of upper extremity function.<sup><xref ref-type="bibr" rid="bibr9-0269216311419882">9</xref>,<xref ref-type="bibr" rid="bibr45-0269216311419882">45</xref>,<xref ref-type="bibr" rid="bibr47-0269216311419882">47</xref>,<xref ref-type="bibr" rid="bibr49-0269216311419882">49</xref>,<xref ref-type="bibr" rid="bibr54-0269216311419882">54</xref>,<xref ref-type="bibr" rid="bibr77-0269216311419882">77</xref></sup> However, many studies have demonstrated improvement in the Musculoskeletal Tumor Society score and International Symposium on Limb Salvage score (MSTS-ISOLS)<sup><xref ref-type="bibr" rid="bibr78-0269216311419882">78</xref></sup> system.<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr16-0269216311419882">16</xref>,<xref ref-type="bibr" rid="bibr57-0269216311419882">57</xref><xref ref-type="bibr" rid="bibr58-0269216311419882"/><xref ref-type="bibr" rid="bibr59-0269216311419882"/><xref ref-type="bibr" rid="bibr60-0269216311419882"/><xref ref-type="bibr" rid="bibr61-0269216311419882"/>–<xref ref-type="bibr" rid="bibr62-0269216311419882">62</xref></sup> This 30-point physician-completed scoring system comprises six levels (0–5) in six domains, including pain, function, emotional acceptance, support, walking and gait. The system was originally described by Enneking et al.<sup><xref ref-type="bibr" rid="bibr78-0269216311419882">78</xref></sup> and subsequently adopted<sup><xref ref-type="bibr" rid="bibr62-0269216311419882">62</xref></sup> by the Musculoskeletal Tumor Society and the International Symposia on Limb Salvage and has low inter-observer variability.</p>
<p>The TESS is a patient-completed validated measure developed to evaluate physical disability in patients treated for extremity tumours<sup><xref ref-type="bibr" rid="bibr79-0269216311419882">79</xref>,<xref ref-type="bibr" rid="bibr80-0269216311419882">80</xref></sup> and includes 30 items on activity limitations in daily life, such as restrictions in body movement, mobility, self-care and performance of daily tasks. Each item is scored from 0 to 5 points and the raw score is converted to a score of 100 points. A higher score indicates less disability. A clinically significant improvement in TESS has been documented following surgical treatment for metastatic bone disease.<sup><xref ref-type="bibr" rid="bibr60-0269216311419882">60</xref>,<xref ref-type="bibr" rid="bibr61-0269216311419882">61</xref></sup></p>
<p>Although some authors have attempted to compare outcomes after conservative and surgical treatment, these studies are limited by their retrospective design and use of non-standard outcome measures.<sup><xref ref-type="bibr" rid="bibr44-0269216311419882">44</xref>,<xref ref-type="bibr" rid="bibr47-0269216311419882">47</xref></sup></p>
<p>Adjuvant postoperative radiotherapy may help to improve physical functioning after surgery. Townsend et al.<sup><xref ref-type="bibr" rid="bibr9-0269216311419882">9</xref></sup> retrospectively compared 35 patients given adjuvant postoperative radiotherapy to 29 treated with surgery alone and showed that patients given radiotherapy were more likely to return to normal function (53% versus 11.5%, <italic>p</italic> &lt; 0.01).</p>
<p>The use of methylmethacrylate bone cement to supplement fracture fixation can also lead to improved functional outcomes by enhancing the stability of the reconstruction and allowing earlier mobilization.<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr56-0269216311419882">56</xref>,<xref ref-type="bibr" rid="bibr81-0269216311419882">81</xref></sup> Habermann et al.<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref></sup> reviewed a group of patients with metastases of the hip or femur and reported that 95% of patients whose fracture fixation was supplemented with cement could walk, compared with 75% of those treated with surgery alone. This effect is of less significance in the humerus, where both intramedullary nailing and plating with cement fixation have a similar effect on function.<sup><xref ref-type="bibr" rid="bibr45-0269216311419882">45</xref></sup></p>
<p>The literature therefore suggests that functional status and QoL can be improved by the surgical treatment of bone metastases, although the level of the evidence is low (level III<sup><xref ref-type="bibr" rid="bibr44-0269216311419882">44</xref>,<xref ref-type="bibr" rid="bibr47-0269216311419882">47</xref></sup> and level IV).<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr9-0269216311419882">9</xref>,<xref ref-type="bibr" rid="bibr16-0269216311419882">16</xref>,<xref ref-type="bibr" rid="bibr26-0269216311419882">26</xref>,<xref ref-type="bibr" rid="bibr27-0269216311419882">27</xref>,<xref ref-type="bibr" rid="bibr30-0269216311419882">30</xref>,<xref ref-type="bibr" rid="bibr32-0269216311419882">32</xref>,<xref ref-type="bibr" rid="bibr44-0269216311419882">44</xref><xref ref-type="bibr" rid="bibr45-0269216311419882"/>–<xref ref-type="bibr" rid="bibr46-0269216311419882">46</xref>,<xref ref-type="bibr" rid="bibr48-0269216311419882">48</xref>,<xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref><xref ref-type="bibr" rid="bibr53-0269216311419882"/>–<xref ref-type="bibr" rid="bibr54-0269216311419882">54</xref>,<xref ref-type="bibr" rid="bibr58-0269216311419882">58</xref>,<xref ref-type="bibr" rid="bibr62-0269216311419882">62</xref>,<xref ref-type="bibr" rid="bibr73-0269216311419882">73</xref>,<xref ref-type="bibr" rid="bibr76-0269216311419882">76</xref>,<xref ref-type="bibr" rid="bibr77-0269216311419882">77</xref>,<xref ref-type="bibr" rid="bibr81-0269216311419882">81</xref></sup></p>
</sec>
<sec id="section12-0269216311419882">
<title>Will patients live long enough to benefit? Predicting survival</title>
<p>The median survival of patients following surgical intervention for metastatic bone disease in the literature ranges from 2 (Hardman et al.<sup><xref ref-type="bibr" rid="bibr76-0269216311419882">76</xref></sup>) to 14 (Giurea et al.<sup><xref ref-type="bibr" rid="bibr73-0269216311419882">73</xref></sup>) months, and there is little difference in survival between those treated surgically and those treated with palliative radiotherapy for bone pain.<sup><xref ref-type="bibr" rid="bibr3-0269216311419882">3</xref></sup> The most important determinants of survival are the biology of the primary cancer and the stage of the disease: patients with metastases from breast cancer have a better prognosis than those with other primary tumours.<sup><xref ref-type="bibr" rid="bibr3-0269216311419882">3</xref>,<xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref><xref ref-type="bibr" rid="bibr7-0269216311419882"/>–<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr19-0269216311419882">19</xref>,<xref ref-type="bibr" rid="bibr22-0269216311419882">22</xref>,<xref ref-type="bibr" rid="bibr27-0269216311419882">27</xref>,<xref ref-type="bibr" rid="bibr32-0269216311419882">32</xref>,<xref ref-type="bibr" rid="bibr45-0269216311419882">45</xref>,<xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref></sup> Similarly, patients with metastases from renal,<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr45-0269216311419882">45</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref></sup> prostatic<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref></sup> or thyroid<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref></sup> cancer, lymphoma<sup><xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref></sup> or myeloma<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref></sup> do better than those with lung,<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr32-0269216311419882">32</xref>,<xref ref-type="bibr" rid="bibr45-0269216311419882">45</xref>,<xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref></sup> gastric or hepatocellular primaries.<sup><xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref></sup> Patients with visceral metastases or multiple bony metastases have a poorer prognosis.<sup><xref ref-type="bibr" rid="bibr3-0269216311419882">3</xref>,<xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref>,<xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref>,<xref ref-type="bibr" rid="bibr83-0269216311419882">83</xref></sup> The six-month survival rates associated with tumours that commonly metastasize to bone have been reported to be 98% for prostate cancer, 89% for breast cancer, 50% for lung cancer and 51% for kidney tumours.<sup><xref ref-type="bibr" rid="bibr14-0269216311419882">14</xref></sup></p>
<p>The biology of the underlying tumour is also reflected in the time it takes for a skeletal metastasis to develop after diagnosis, which in some studies is prognostic for survival.<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref>,<xref ref-type="bibr" rid="bibr84-0269216311419882">84</xref></sup> Bohm and Huber<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref></sup> found an interval of more than three years was a good prognostic variable. Durr et al.<sup><xref ref-type="bibr" rid="bibr84-0269216311419882">84</xref></sup> found a latent period of over 12 months to be significant in patients with renal cancer, but not in those with breast cancer.<sup><xref ref-type="bibr" rid="bibr83-0269216311419882">83</xref></sup> In the latter group, patients with fewer than three months of symptoms had a poorer prognosis than others.<sup><xref ref-type="bibr" rid="bibr83-0269216311419882">83</xref></sup></p>
<p>Pathological fracture is associated with poorer survival.<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr76-0269216311419882">76</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref>,<xref ref-type="bibr" rid="bibr83-0269216311419882">83</xref></sup> Katzer et al.<sup><xref ref-type="bibr" rid="bibr54-0269216311419882">54</xref></sup> found shorter overall survival for patients with pathologic fracture (10.3 months) than for patients undergoing prophylactic stabilization (16.2 months), although this was not statistically significant. Hardman et al.<sup><xref ref-type="bibr" rid="bibr76-0269216311419882">76</xref></sup> reported a significantly (<italic>p</italic> &lt; 0.0001) higher median postoperative survival of patients with prophylactic surgery (15 months) compared with those with fracture (2 months). Unfortunately, selection bias makes it difficult to draw generalizable conclusions from these studies.</p>
<p>Similarly, survival has been related to the extent of skeletal involvement,<sup><xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref></sup> the use of postoperative radiotherapy,<sup><xref ref-type="bibr" rid="bibr9-0269216311419882">9</xref>,<xref ref-type="bibr" rid="bibr85-0269216311419882">85</xref></sup> surgical margin,<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr73-0269216311419882">73</xref></sup> type of procedure (arthroplasty versus fracture fixation)<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr9-0269216311419882">9</xref></sup> and use of bone cement to supplement fixation.<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref></sup></p>
<p>Predicting the likely survival of the patient is an important part of the decision to operate, and several systems are described in the literature, although none have been prospectively validated.<sup><xref ref-type="bibr" rid="bibr19-0269216311419882">19</xref>,<xref ref-type="bibr" rid="bibr70-0269216311419882">70</xref>,<xref ref-type="bibr" rid="bibr74-0269216311419882">74</xref>,<xref ref-type="bibr" rid="bibr82-0269216311419882">82</xref>,<xref ref-type="bibr" rid="bibr86-0269216311419882">86</xref><xref ref-type="bibr" rid="bibr87-0269216311419882"/>–<xref ref-type="bibr" rid="bibr88-0269216311419882">88</xref></sup></p>
</sec>
<sec id="section13-0269216311419882">
<title>Predicting a fracture</title>
<p>Clinicians are often asked to consider prophylactic internal fixation in patients with established metastatic bone disease where there is a perceived risk of fracture. The major benefit of this approach is that patients can be treated in a planned semi-elective fashion, which may lead to better outcomes. The difficulty is that, given that a fracture cannot be reliably predicted, some patients may undergo a procedure they would not otherwise have needed. Scoring systems (<xref ref-type="table" rid="table1-0269216311419882">Table 1</xref>) have been developed to help with this decision, the Mirels and Harrington systems being the two most widely adopted.<sup><xref ref-type="bibr" rid="bibr89-0269216311419882">89</xref></sup> A rough estimate of the percentage probability of fracture<sup><xref ref-type="bibr" rid="bibr19-0269216311419882">19</xref></sup> can be calculated by multiplying the quotient of the diameter of the lesion and bone by 100. Zickel and Mouradian<sup><xref ref-type="bibr" rid="bibr42-0269216311419882">42</xref></sup> have proposed the concept of the femur at high risk of fracture. Although these systems can be helpful, it is telling that they are underutilized.<sup><xref ref-type="bibr" rid="bibr11-0269216311419882">11</xref></sup></p>
<table-wrap id="table1-0269216311419882" position="float">
<label>Table 1.</label>
<caption>
<p>Commonly used radiological criteria to predict fracture.</p>
</caption>
<graphic alternate-form-of="table1-0269216311419882" xlink:href="10.1177_0269216311419882-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Variables</th>
<th align="left">Criteria for surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="4"><bold>Harrington</bold><break/>(Proximal femoral fracture)</td>
<td>Size</td>
<td>≥2.5cm</td>
</tr>
<tr>
<td>Bone diameter</td>
<td>≥50%</td>
</tr>
<tr>
<td>Lesser trochanter involvement</td>
<td>Fracture</td>
</tr>
<tr>
<td>Response to RT</td>
<td>No response</td>
</tr>
<tr>
<td rowspan="4"><bold>Mirels</bold></td>
<td>Pain (1-3)</td>
<td rowspan="4">Cumulative score ≥8</td>
</tr>
<tr>
<td>Size (1-3)</td>
</tr>
<tr>
<td>Type (1-3)</td>
</tr>
<tr>
<td>Anatomic location (1-3)</td>
</tr>
<tr>
<td rowspan="3"><bold>Beals</bold></td>
<td>Size</td>
<td rowspan="3">Painful cortical lesion &gt;2.5 cm<break/>Painful intramedullary &gt;50% diameter</td>
</tr>
<tr>
<td>Cortical involvement</td>
</tr>
<tr>
<td>Pain</td>
</tr>
<tr>
<td rowspan="4"><bold>Zickel</bold></td>
<td>Lysis</td>
<td rowspan="4">Presence of these signify high risk of fracture</td>
</tr>
<tr>
<td>Malignant change</td>
</tr>
<tr>
<td>Cortical involvement</td>
</tr>
<tr>
<td>Pain</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Harrington’s system<sup><xref ref-type="bibr" rid="bibr90-0269216311419882">90</xref></sup> (<xref ref-type="table" rid="table1-0269216311419882">Table 1</xref>) is easy to remember, but has not been evaluated prospectively or rigorously. Furthermore, although the criteria are extremely specific, they are poorly sensitive, and other potentially important factors (e.g. patient weight, co-morbidities, compliance, pain, local tenderness, pain medications, bisphosphonates, concurrent chemotherapy, function, primary disease, life expectancy, specific sites other than proximal femur, matrix of lesion, other lesions, concurrent disease, radiosensitivity, patient activity level and patient expectations) are not considered.<sup><xref ref-type="bibr" rid="bibr89-0269216311419882">89</xref></sup> Aaron<sup><xref ref-type="bibr" rid="bibr91-0269216311419882">91</xref></sup> states that these criteria are guidelines and should not be strict rules, as for the lesions to become apparent on plain radiographs bone loss must approach 30%–50%. Moreover, in lesions characterized by bone production, clear evidence of bone destruction can be difficult to assess on plain radiographs.</p>
<p>The Mirels<sup><xref ref-type="bibr" rid="bibr13-0269216311419882">13</xref></sup> system (<xref ref-type="table" rid="table1-0269216311419882">Table 1</xref>) has the advantages of being relatively simple, (needing only clinical evaluation and radiographs), reproducible and valid, and has been more rigorously evaluated than Harrington’s. It is highly sensitive as a screening tool (85%–91%), and possibly even better than clinical judgment using the same clinical information and plain radiographs.<sup><xref ref-type="bibr" rid="bibr89-0269216311419882">89</xref></sup> The disadvantages include the fact that it has not been evaluated prospectively, overlooks between 9% and 15% of patients who will have a fracture, has relatively poor specificity (33%–35%) in predicting actual fracture and does not account for numerous potentially important non-mechanical factors.<sup><xref ref-type="bibr" rid="bibr89-0269216311419882">89</xref></sup> A critical evaluation of the Mirels rating system by Damron et al.<sup><xref ref-type="bibr" rid="bibr92-0269216311419882">92</xref></sup> showed good agreement for site, moderate agreement for type and fair agreement for size and pain between observers. They reported no significant difference over clinical judgment regardless of experience level. They concluded that although Mirels’ system was reproducible, valid and more sensitive than clinical judgment, more specific parameters were needed.</p>
<p>Other systems include the criteria proposed by Beals et al.<sup><xref ref-type="bibr" rid="bibr93-0269216311419882">93</xref></sup> (<xref ref-type="table" rid="table1-0269216311419882">Table 1</xref>), which have since been extended,<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr19-0269216311419882">19</xref>,<xref ref-type="bibr" rid="bibr27-0269216311419882">27</xref><xref ref-type="bibr" rid="bibr28-0269216311419882"/>–<xref ref-type="bibr" rid="bibr29-0269216311419882">29</xref></sup> and the well-accepted predictors of impending fractures are a painful lytic lesion involving more than 2.5 cm of the cortex; a painful intramedullary lytic lesion involving more than 50% of the cross-sectional diameter of the bone; and a progressive painful lesion not relieved by radiotherapy. Another system identified that a rough estimate of the percentage probability of fracture<sup><xref ref-type="bibr" rid="bibr19-0269216311419882">19</xref></sup> can be calculated by multiplying the quotient of the diameter of the lesion and bone by 100.</p>
<p>While these systems can be helpful, the clinician should consider the whole patient when deciding about surgical fixation.</p>
</sec>
<sec id="section14-0269216311419882">
<title>When to operate?</title>
<p>Unfortunately, resolving the published literature into a decision about operating on an individual patient can still be difficult. Publications may reflect a number of different philosophies of treatment, ranging from a largely conservative approach to the aggressive pursuit of surgical fixation whenever feasible. Although it can be helpful and rational to combine scoring systems for predicting fracture and survival, ultimately the decision to operate is an individualized one. Predicting survival is difficult and it may be best to assume that the patient will live longer than one anticipates.<sup><xref ref-type="bibr" rid="bibr14-0269216311419882">14</xref></sup></p>
<p>In the presence of a pathological fracture rendering the patient bed-bound, the decision to operate may be more straightforward, unless the patient is moribund. Given the difficulty of managing the significant unpredictable incident pain associated with fracture, and the rapid early relief of pain associated with surgical fixation, the conventional view that the recovery time from surgery should not be more than the patient’s life expectancy (a suggested minimum of 30–90 days survival<sup><xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr22-0269216311419882">22</xref>,<xref ref-type="bibr" rid="bibr27-0269216311419882">27</xref>,<xref ref-type="bibr" rid="bibr28-0269216311419882">28</xref>,<xref ref-type="bibr" rid="bibr30-0269216311419882">30</xref>,<xref ref-type="bibr" rid="bibr34-0269216311419882">34</xref>,<xref ref-type="bibr" rid="bibr77-0269216311419882">77</xref>,<xref ref-type="bibr" rid="bibr81-0269216311419882">81</xref></sup>) may not always be appropriate. The expertise of a palliative care team in this situation is very helpful in providing a global overview of the patient’s symptoms and prognosis and in providing alternatives to surgery, such as epidural analgesia.</p>
<p>Upper extremity fractures may more often be treated conservatively than those that affect the mobility of the patient. For example, if a patient sustains a fracture of the humerus during chemotherapy, it may be possible to treat this conservatively until there is a suitable window in the systemic treatment. In some cases, a good response to treatment can lead to fracture healing.</p>
<p>In less acute situations, the decision to operate is based on the patient’s general condition, the expected duration and QoL with or without a successful operation.<sup><xref ref-type="bibr" rid="bibr94-0269216311419882">94</xref></sup> No patient should be denied surgery on the basis of extensive bone destruction, as contemporary orthopaedic oncology techniques allow for replacement or stabilization of extensive bone involvement.<sup><xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr23-0269216311419882">23</xref>,<xref ref-type="bibr" rid="bibr77-0269216311419882">77</xref>,<xref ref-type="bibr" rid="bibr81-0269216311419882">81</xref></sup> The quality of bone should influence only the choice of internal fixation device.<sup><xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr77-0269216311419882">77</xref></sup> From the oncological point of view, orthopaedic surgery may offer the only dependable treatment for some metastases (e.g. some renal metastases).<sup><xref ref-type="bibr" rid="bibr3-0269216311419882">3</xref></sup></p>
<p>Capanna et al.<sup><xref ref-type="bibr" rid="bibr95-0269216311419882">95</xref></sup> have provided a rational guideline for indications for surgery, the type of operation to be undertaken and the methods of reconstruction available. The aim is to offer adequate individual treatment to the patient, avoiding undertreatment or overtreatment, to achieve control of pain and to manage impending and pathological fractures so that longer survival is associated with a better QoL.</p>
</sec>
<sec id="section15-0269216311419882">
<title>When not to operate?</title>
<p>Contraindications to surgery can be described as patient specific, disease specific and procedure specific.<sup><xref ref-type="bibr" rid="bibr24-0269216311419882">24</xref></sup> The patient’s overall physical and emotional state, and willingness and ability to participate in rehabilitation, are important considerations and prolonged postponement of surgery should be avoided, as the patient might deteriorate and the risks of surgery increase. Relative contraindications to surgery<sup><xref ref-type="bibr" rid="bibr24-0269216311419882">24</xref>,<xref ref-type="bibr" rid="bibr30-0269216311419882">30</xref></sup> include a moribund patient, mental obtundation, haematopoietic depression, an infected wound in the surgical region, an acute deep venous thrombosis (especially if accompanied by pulmonary embolism), extensive neurovascular encasement by soft tissue tumour extension, general debility, severe malnutrition precluding wound healing, expected survival too short for the patient to recover sufficiently to benefit from the operative treatment and metastases in other sites compromising function.</p>
<p>With the exception of the patients discussed above, the general rule is that the recovery time from surgery should not exceed the life expectancy, but authors vary on where to draw the line. Life expectancies of less than four weeks,<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr18-0269216311419882">18</xref>,<xref ref-type="bibr" rid="bibr27-0269216311419882">27</xref><xref ref-type="bibr" rid="bibr28-0269216311419882"/>–<xref ref-type="bibr" rid="bibr29-0269216311419882">29</xref>,<xref ref-type="bibr" rid="bibr56-0269216311419882">56</xref></sup> six weeks<sup><xref ref-type="bibr" rid="bibr22-0269216311419882">22</xref>,<xref ref-type="bibr" rid="bibr77-0269216311419882">77</xref></sup> and three months<sup><xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr34-0269216311419882">34</xref>,<xref ref-type="bibr" rid="bibr41-0269216311419882">41</xref></sup> have all been stated to be major contraindications to surgery. However, it is clear that consideration of the individual patient’s circumstances is important.</p>
</sec>
<sec id="section16-0269216311419882">
<title>Complications of surgery</title>
<p>There are significant risks associated with complex surgical interventions in patients with metastatic bone disease; cumulative complication rates as high as 38% have been reported.<sup><xref ref-type="bibr" rid="bibr76-0269216311419882">76</xref></sup> Major complications include peri-operative mortality, local recurrence, fixation failure, infection and thromboembolism. Mortality in the peri-operative period after surgery for metastatic bone disease is high, with rates ranging from 6% to 15%.<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr35-0269216311419882">35</xref>,<xref ref-type="bibr" rid="bibr39-0269216311419882">39</xref>,<xref ref-type="bibr" rid="bibr48-0269216311419882">48</xref>,<xref ref-type="bibr" rid="bibr54-0269216311419882">54</xref>,<xref ref-type="bibr" rid="bibr62-0269216311419882">62</xref></sup> Tan et al.<sup><xref ref-type="bibr" rid="bibr48-0269216311419882">48</xref></sup> reported a mortality of 10% after surgery for pathological fracture and after prophylactic fixation but a higher mortality of 33.3% in the mixed group, who had surgery for both pathological fractures and prophylactic fixation. Multiple fixations attempted at the same operative sessions were associated with a 50% mortality.</p>
<p>The local recurrence rate after surgical excision is as high as 25%,<sup><xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref></sup> but depends on the completeness of surgical excision. Extralesional resection of pelvic metastases is associated with a lower risk of local recurrence than intralesional resection.<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref>,<xref ref-type="bibr" rid="bibr73-0269216311419882">73</xref></sup> Appropriate surgical reconstruction can continue to benefit the patient, despite local recurrence. In one study, local recurrence was identified in 25% of patients who had undergone acetabular reconstruction, but in only 8% had the reconstruction failed.<sup><xref ref-type="bibr" rid="bibr52-0269216311419882">52</xref></sup></p>
<p>The risk that the fixation will fail increases with time.<sup><xref ref-type="bibr" rid="bibr32-0269216311419882">32</xref>,<xref ref-type="bibr" rid="bibr46-0269216311419882">46</xref>,<xref ref-type="bibr" rid="bibr75-0269216311419882">75</xref></sup> Yazawa et al.<sup><xref ref-type="bibr" rid="bibr32-0269216311419882">32</xref></sup> (<italic>N</italic> = 147) reported an overall failure rate of 8.2%, but estimated the probability of fixation failure as 33% at 60 months, and this was even greater for femoral lesions (44% at 60 months). Proximal femoral lesions treated with compression screws and nail plates had a high (23%) failure rate. In a series of 233 procedures in 199 surgically treated patients, Dijkstra et al.<sup><xref ref-type="bibr" rid="bibr46-0269216311419882">46</xref></sup> noted that 11% of implanted devices failed (cumulative probability 40% after 60 months). The probability of failure at four years was 10% for endoprostheses but 70% for angled blade blades in the femur. Bohm and Huber<sup><xref ref-type="bibr" rid="bibr6-0269216311419882">6</xref></sup> (<italic>N</italic> = 94) reported a local failure rate of 0% after biological reconstruction, 3.6% after cemented or uncemented osteosynthesis and 1.8% after prosthetic replacement. In a review of 142 patients who had undergone surgery for proximal femur lesions, Wedin and Bauer<sup><xref ref-type="bibr" rid="bibr75-0269216311419882">75</xref></sup> reported a 10.3% failure rate in the endoprosthetic group as compared with 16.2% in fixation group. The re-operation rate was lower (8.3%) in the endoprosthetic group as compared with the internal fixation group (16.2%). This could, however, be related to the higher survival rate in the re-operation group (15 months) as compared with that (5 months) of patients not requiring further surgery. The authors report that the risk of re-operation increases with time (being 0.14 at one year and 0.20 at two years). The two-year risk for re-operation after any type of osteosynthesis was estimated as 0.35 as compared with 0.18 after endoprosthetic replacement. They concluded that endoprosthetic replacement is superior to fixation as it replaces bone, while osteosynthetic implants at best are load sharing and are more likely to fail, although the use of methylmethacrylate as a supplement to an internal fixation device may reduce the chance of failure.<sup><xref ref-type="bibr" rid="bibr7-0269216311419882">7</xref>,<xref ref-type="bibr" rid="bibr8-0269216311419882">8</xref>,<xref ref-type="bibr" rid="bibr81-0269216311419882">81</xref></sup></p>
<p>There is also a risk of systemic (thromboembolic, cardiac, pulmonary, cerebrovascular events) and local complications. Katzer et al.<sup><xref ref-type="bibr" rid="bibr54-0269216311419882">54</xref></sup> (<italic>N</italic> = 101) reported a systemic complication rate of 14.5% (excluding mortality), six-week mortality of 7.9%, and local complication rate of 24.8% in the operated area, leading to a revision rate of 8.5%.</p>
<p>The role of adjuvant radiotherapy in the postoperative period in preventing failure is uncertain. In one study, postoperative radiotherapy was found to significantly lower the incidence of a second procedure at the same site.<sup><xref ref-type="bibr" rid="bibr9-0269216311419882">9</xref></sup> In contrast, Haentjens et al.<sup><xref ref-type="bibr" rid="bibr53-0269216311419882">53</xref></sup> reported that the incidence of bone remodelling and healing after adjuvant radiotherapy was significantly (<italic>p</italic> &lt; 0.01) lower than after surgery alone.</p>
</sec>
</sec>
<sec id="section17-0269216311419882" sec-type="discussion">
<title>Discussion</title>
<p>The decision to operate on a patient with metastatic bone disease is often difficult and requires an understanding of the underlying disease, the demands of the patient and the principles of surgical treatment of bone metastases. Approaches that consider the biological activity of bone lesion, responsiveness of the bone lesion to medical and radiation therapy and the anatomic location of the bone metastasis and patient factors (e.g. health status, expected length of survival, compliance, and patient expectation and needs) are helpful.<sup><xref ref-type="bibr" rid="bibr12-0269216311419882">12</xref></sup> Although scoring systems can be used to help predict the risk of fracture, in patients who have not yet had a fracture, these other considerations are often of equal importance. The decision to operate once a fracture has occurred is sometimes easier, but conservative treatment may be appropriate for selected patients with a very poor prognosis.</p>
<p>Surgical management of metastatic bone disease has been recently discussed,<sup><xref ref-type="bibr" rid="bibr5-0269216311419882">5</xref>,<xref ref-type="bibr" rid="bibr14-0269216311419882">14</xref></sup> but these papers have mainly concentrated on the technical aspect of the problem and not on the impact on QoL, as approached in this review. Our study is limited by an alteration in the search methodology for 2009, because of the non-availability of the original ‘Dialog Datastar’ database search tool. However, a Pubmed search did not reveal any clinical article published in 2009 that could have been included in this review.</p>
<p>Timely and appropriate surgical intervention reliably alleviates pain and improves QoL and can be undertaken with few complications in most patients.<sup><xref ref-type="bibr" rid="bibr26-0269216311419882">26</xref></sup> Although most procedures can be undertaken by non-specialists, consultation with other members of the multidisciplinary team is mandatory, and in complex cases, referral to a specialist orthopaedic oncology centre can be helpful. Further research, particularly around decision making in this challenging and heterogenous group of patients, may be of great benefit.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that there is no conflict of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269216311419882">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berrettoni</surname><given-names>BA</given-names></name>
<name><surname>Carter</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Mechanisms of cancer metastasis to bone</article-title>. <source>J Bone Joint Surg Am</source> <year>1986</year>; <volume>68</volume>: <fpage>308</fpage>–<lpage>312</lpage>.</citation>
</ref>
<ref id="bibr2-0269216311419882">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simon</surname><given-names>MA</given-names></name>
<name><surname>Bartucci</surname><given-names>EJ</given-names></name>
</person-group>. <article-title>The search for the primary tumor in patients with skeletal metastases of unknown origin</article-title>. <source>Cancer</source> <year>1986</year>; <volume>58</volume>: <fpage>1088</fpage>–<lpage>1095</lpage>.</citation>
</ref>
<ref id="bibr3-0269216311419882">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Controversies in the surgical management of skeletal metastases</article-title>. <source>J Bone Joint Surg Br</source> <year>2005</year>; <volume>87</volume>: <fpage>608</fpage>–<lpage>617</lpage>.</citation>
</ref>
<ref id="bibr4-0269216311419882">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hage</surname><given-names>WD</given-names></name>
<name><surname>Aboulafia</surname><given-names>AJ</given-names></name>
<name><surname>Aboulafia</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Incidence, location, and diagnostic evaluation of metastatic bone disease</article-title>. <source>Orthop Clin North Am</source> <year>2000</year>; <volume>31</volume>: <fpage>515</fpage>–<lpage>528</lpage>, vii.</citation>
</ref>
<ref id="bibr5-0269216311419882">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bickels</surname><given-names>J</given-names></name>
<name><surname>Dadia</surname><given-names>S</given-names></name>
<name><surname>Lidar</surname><given-names>Z</given-names></name>
</person-group>. <article-title>Surgical management of metastatic bone disease</article-title>. <source>J Bone Joint Surg Am</source> <year>2009</year>; <volume>91</volume>: <fpage>1503</fpage>–<lpage>1516</lpage>.</citation>
</ref>
<ref id="bibr6-0269216311419882">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bohm</surname><given-names>P</given-names></name>
<name><surname>Huber</surname><given-names>J</given-names></name>
</person-group>. <article-title>The surgical treatment of bony metastases of the spine and limbs</article-title>. <source>J Bone Joint Surg Br</source> <year>2002</year>; <volume>84</volume>: <fpage>521</fpage>–<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr7-0269216311419882">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Habermann</surname><given-names>ET</given-names></name>
<name><surname>Sachs</surname><given-names>R</given-names></name>
<name><surname>Stern</surname><given-names>RE</given-names></name>
<name><surname>Hirsh</surname><given-names>DM</given-names></name>
<name><surname>Anderson</surname><given-names>WJ</given-names><suffix>Jr.</suffix></name>
</person-group> <article-title>The pathology and treatment of metastatic disease of the femur</article-title>. <source>Clin Orthop Relat Res</source> <year>1982</year>; <volume>169</volume>:<fpage>70</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr8-0269216311419882">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrington</surname><given-names>KD</given-names></name>
<name><surname>Sim</surname><given-names>FH</given-names></name>
<name><surname>Enis</surname><given-names>JE</given-names></name>
<name><surname>Johnston</surname><given-names>JO</given-names></name>
<name><surname>Diok</surname><given-names>HM</given-names></name>
<name><surname>Gristina</surname><given-names>AG</given-names></name>
</person-group>. <article-title>Methylmethacrylate as an adjunct in internal fixation of pathological fractures. Experience with three hundred and seventy-five cases</article-title>. <source>J Bone Joint Surg Am</source> <year>1976</year>; <volume>58</volume>: <fpage>1047</fpage>–<lpage>1055</lpage>.</citation>
</ref>
<ref id="bibr9-0269216311419882">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Townsend</surname><given-names>PW</given-names></name>
<name><surname>Rosenthal</surname><given-names>HG</given-names></name>
<name><surname>Smalley</surname><given-names>SR</given-names></name>
<name><surname>Cozad</surname><given-names>SC</given-names></name>
<name><surname>Hassanein</surname><given-names>RE</given-names></name>
</person-group>. <article-title>Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopedic stabilization of impending or pathologic fractures due to metastatic disease</article-title>. <source>J Clin Oncol</source> <year>1994</year>; <volume>12</volume>: <fpage>2345</fpage>–<lpage>2350</lpage>.</citation>
</ref>
<ref id="bibr10-0269216311419882">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Savage</surname><given-names>PD</given-names></name>
<name><surname>Ward</surname><given-names>WG</given-names></name>
</person-group>. <article-title>Medical management of metastatic skeletal disease</article-title>. <source>Orthop Clin North Am</source> <year>2000</year>; <volume>31</volume>: <fpage>545</fpage>–<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr11-0269216311419882">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cumming</surname><given-names>D</given-names></name>
<name><surname>Cumming</surname><given-names>J</given-names></name>
<name><surname>Vince</surname><given-names>A</given-names></name>
<name><surname>Benson</surname><given-names>R</given-names></name>
</person-group>. <article-title>Metastatic bone disease: the requirement for improvement in a multidisciplinary approach</article-title>. <source>Int Orthop</source> <year>2009</year>; <volume>33</volume>: <fpage>493</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr12-0269216311419882">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rougraff</surname><given-names>B</given-names></name>
</person-group>. <article-title>Indications for operative treatment</article-title>. <source>Orthop Clin North Am</source> <year>2000</year>; <volume>31</volume>: <fpage>567</fpage>–<lpage>575</lpage>, <comment>viii</comment>.</citation>
</ref>
<ref id="bibr13-0269216311419882">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mirels</surname><given-names>H</given-names></name>
</person-group>. <article-title>Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures</article-title>. <source>Clin Orthop Relat Res</source> <year>1989</year>; <volume>249</volume>: <fpage>256</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr14-0269216311419882">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Biermann</surname><given-names>JS</given-names></name>
<name><surname>Holt</surname><given-names>GE</given-names></name>
<name><surname>Lewis</surname><given-names>VO</given-names></name>
<name><surname>Schwartz</surname><given-names>HS</given-names></name>
<name><surname>Yaszemski</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Metastatic bone disease: diagnosis, evaluation, and treatment</article-title>. <source>J Bone Joint Surg Am</source> <year>2009</year>; <volume>91</volume>: <fpage>1518</fpage>–<lpage>1530</lpage>.</citation>
</ref>
<ref id="bibr15-0269216311419882">
<label>15.</label>
<citation citation-type="book">
<person-group person-group-type="editor">
<name><surname>Delea</surname><given-names>T</given-names></name>
<name><surname>Langer</surname><given-names>C</given-names></name>
<name><surname>McKiernan</surname><given-names>J</given-names></name>
<name><surname>Liss</surname><given-names>M</given-names></name>
<name><surname>Edelsberg</surname><given-names>J</given-names></name>
<name><surname>Brandman</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer</article-title>. <source>Oncology</source> <year>2004</year>; <volume>67</volume>: <fpage>390</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr16-0269216311419882">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eckardt</surname><given-names>JJ</given-names></name>
<name><surname>Kabo</surname><given-names>JM</given-names></name>
<name><surname>Kelly</surname><given-names>CM</given-names></name>
<name><surname>Ward</surname><given-names>WG</given-names><suffix>Sr.</suffix></name>
<name><surname>Cannon</surname><given-names>CP</given-names></name>
</person-group>. <article-title>Endoprosthetic reconstructions for bone metastases</article-title>. <source>Clin Orthop Relat Res</source> <year>2003</year>; <volume>415</volume> <supplement>Suppl</supplement>: <fpage>S254</fpage>–<lpage>S262</lpage>.</citation>
</ref>
<ref id="bibr17-0269216311419882">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galasko</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Pathological fractures secondary to metastatic cancer</article-title>. <source>J R Coll Surg Edinb</source> <year>1974</year>; <volume>19</volume>: <fpage>351</fpage>–<lpage>362</lpage>.</citation>
</ref>
<ref id="bibr18-0269216311419882">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galasko</surname><given-names>CS</given-names></name>
</person-group>. <article-title>The management of skeletal metastases</article-title>. <source>J R Coll Surg Edinb</source> <year>1980</year>; <volume>25</volume>: <fpage>144</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr19-0269216311419882">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mandi</surname><given-names>A</given-names></name>
<name><surname>Szepesi</surname><given-names>K</given-names></name>
<name><surname>Morocz</surname><given-names>I</given-names></name>
</person-group>. <article-title>Surgical treatment of pathologic fractures from metastatic tumors of long bones</article-title>. <source>Orthopedics</source> <year>1991</year>; <volume>14</volume>: <fpage>43</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr20-0269216311419882">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marcove</surname><given-names>RC</given-names></name>
<name><surname>Yang</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Survival times after treatment of pathologic fractures</article-title>. <source>Cancer</source> <year>1967</year>; <volume>20</volume>: <fpage>2154</fpage>–<lpage>2158</lpage>.</citation>
</ref>
<ref id="bibr21-0269216311419882">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koskinen</surname><given-names>EV</given-names></name>
<name><surname>Nieminen</surname><given-names>RA</given-names></name>
</person-group>. <article-title>Surgical treatment of metastatic pathological fracture of major long bones</article-title>. <source>Acta Orthop Scand</source> <year>1973</year>; <volume>44</volume>: <fpage>539</fpage>–<lpage>549</lpage>.</citation>
</ref>
<ref id="bibr22-0269216311419882">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parrish</surname><given-names>FF</given-names></name>
<name><surname>Murray</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Surgical treatment for secondary neoplastic fractures. A retrospective study of ninety-six patients</article-title>. <source>J Bone Joint Surg Am</source> <year>1970</year>; <volume>52</volume>: <fpage>665</fpage>–<lpage>686</lpage>.</citation>
</ref>
<ref id="bibr23-0269216311419882">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ryan</surname><given-names>JR</given-names></name>
<name><surname>Rowe</surname><given-names>DE</given-names></name>
<name><surname>Salciccioli</surname><given-names>GG</given-names></name>
</person-group>. <article-title>Prophylactic internal fixation of the femur for neoplastic lesions</article-title>. <source>J Bone Joint Surg Am</source> <year>1976</year>; <volume>58</volume>: <fpage>1071</fpage>–<lpage>1074</lpage>.</citation>
</ref>
<ref id="bibr24-0269216311419882">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ward</surname><given-names>WG</given-names></name>
<name><surname>Holsenbeck</surname><given-names>S</given-names></name>
<name><surname>Dorey</surname><given-names>FJ</given-names></name>
<name><surname>Spang</surname><given-names>J</given-names></name>
<name><surname>Howe</surname><given-names>D</given-names></name>
</person-group>. <article-title>Metastatic disease of the femur: surgical treatment</article-title>. <source>Clin Orthop Relat Res</source> <year>2003</year>; <volume>415</volume> <supplement>Suppl</supplement>: <fpage>S230</fpage>–<lpage>S244</lpage>.</citation>
</ref>
<ref id="bibr25-0269216311419882">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ward</surname><given-names>WG</given-names></name>
<name><surname>Spang</surname><given-names>J</given-names></name>
<name><surname>Howe</surname><given-names>D</given-names></name>
</person-group>. <article-title>Metastatic disease of the femur. Surgical management</article-title>. <source>Orthop Clin North Am</source> <year>2000</year>; <volume>31</volume>: <fpage>633</fpage>–<lpage>645</lpage>.</citation>
</ref>
<ref id="bibr26-0269216311419882">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Algan</surname><given-names>SM</given-names></name>
<name><surname>Horowitz</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Surgical treatment of pathologic hip lesions in patients with metastatic disease</article-title>. <source>Clin Orthop Relat Res</source> <year>1996</year>; <volume>332</volume>: <fpage>223</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr27-0269216311419882">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broos</surname><given-names>P</given-names></name>
<name><surname>Reynders</surname><given-names>P</given-names></name>
<name><surname>van den Bogert</surname><given-names>W</given-names></name>
<name><surname>Vanderschot</surname><given-names>P</given-names></name>
</person-group>. <article-title>Surgical treatment of metastatic fracture of the femur improvement of quality of life</article-title>. <source>Acta Orthop Belg</source> <year>1993</year>; <volume>59</volume> <issue>Suppl 1</issue>: <fpage>52</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr28-0269216311419882">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Broos</surname><given-names>PL</given-names></name>
<name><surname>Rommens</surname><given-names>PM</given-names></name>
<name><surname>Vanlangenaker</surname><given-names>MJ</given-names></name>
</person-group>. <article-title>Pathological fractures of the femur: improvement of quality of life after surgical treatment</article-title>. <source>Arch Orthop Trauma Surg</source> <year>1992</year>; <volume>111</volume>: <fpage>73</fpage>–<lpage>77</lpage>.</citation>
</ref>
<ref id="bibr29-0269216311419882">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fourneau</surname><given-names>I</given-names></name>
<name><surname>Broos</surname><given-names>P</given-names></name>
</person-group>. <article-title>Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures</article-title>. <source>Acta Chir Belg</source> <year>1998</year>; <volume>98</volume>: <fpage>255</fpage>–<lpage>260</lpage>.</citation>
</ref>
<ref id="bibr30-0269216311419882">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kelly</surname><given-names>CM</given-names></name>
<name><surname>Wilkins</surname><given-names>RM</given-names></name>
<name><surname>Eckardt</surname><given-names>JJ</given-names></name>
<name><surname>Ward</surname><given-names>WG</given-names></name>
</person-group>. <article-title>Treatment of metastatic disease of the tibia</article-title>. <source>Clin Orthop Relat Res</source> <year>2003</year>; <volume>415</volume> <supplement>Suppl</supplement>: <fpage>S219</fpage>–<lpage>S229</lpage>.</citation>
</ref>
<ref id="bibr31-0269216311419882">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bocchi</surname><given-names>L</given-names></name>
<name><surname>Lazzeroni</surname><given-names>L</given-names></name>
<name><surname>Maggi</surname><given-names>M</given-names></name>
</person-group>. <article-title>The surgical treatment of metastases in long bones</article-title>. <source>Ital J Orthop Traumatol</source> <year>1988</year>; <volume>14</volume>: <fpage>167</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr32-0269216311419882">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yazawa</surname><given-names>Y</given-names></name>
<name><surname>Frassica</surname><given-names>FJ</given-names></name>
<name><surname>Chao</surname><given-names>EY</given-names></name>
<name><surname>Pritchard</surname><given-names>DJ</given-names></name>
<name><surname>Sim</surname><given-names>FH</given-names></name>
<name><surname>Shives</surname><given-names>TC</given-names></name>
</person-group>. <article-title>Metastatic bone disease. A study of the surgical treatment of 166 pathologic humeral and femoral fractures</article-title>. <source>Clin Orthop Relat Res</source> <year>1990</year>; <volume>251</volume>: <fpage>213</fpage>–<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr33-0269216311419882">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tarn</surname><given-names>TS</given-names></name>
<name><surname>Lee</surname><given-names>TS</given-names></name>
</person-group>. <article-title>Surgical treatment of metastatic tumors of the long bones</article-title>. <source>Zhonghua Yi Xue Za Zhi (Taipei)</source> <year>1994</year>; <volume>54</volume>: <fpage>170</fpage>–<lpage>175</lpage>.</citation>
</ref>
<ref id="bibr34-0269216311419882">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Iwamoto</surname><given-names>Y</given-names></name>
<name><surname>Sugioka</surname><given-names>Y</given-names></name>
<name><surname>Chuman</surname><given-names>H</given-names></name>
<name><surname>Shiba</surname><given-names>K</given-names></name>
<name><surname>Yuge</surname><given-names>I</given-names></name>
</person-group>. <article-title>Surgical treatment of metastatic tumors of long bones and the spine</article-title>. <source>Adv Exp Med Biol</source> <year>1992</year>; <volume>324</volume>: <fpage>295</fpage>–<lpage>303</lpage>.</citation>
</ref>
<ref id="bibr35-0269216311419882">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bremner</surname><given-names>RA</given-names></name>
<name><surname>Jelliffe</surname><given-names>AM</given-names></name>
</person-group>. <article-title>The management of pathological fracture of the major long bones from metastatic cancer</article-title>. <source>J Bone Joint Surg Br</source> <year>1958</year>; <volume>40-B</volume>: <fpage>652</fpage>–<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr36-0269216311419882">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Critchley</surname><given-names>JE</given-names></name>
</person-group>. <article-title>The surgical treatment of metastatic malignant deposits in long bones</article-title>. <source>Aust N Z J Surg</source> <year>1971</year>; <volume>40</volume>: <fpage>278</fpage>–<lpage>284</lpage>.</citation>
</ref>
<ref id="bibr37-0269216311419882">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dwars</surname><given-names>BJ</given-names></name>
<name><surname>Patka</surname><given-names>P</given-names></name>
<name><surname>van Mourik</surname><given-names>JC</given-names></name>
</person-group>. <article-title>Surgical treatment of pathological fractures caused by bone metastases</article-title>. <source>Neth J Surg</source> <year>1985</year>; <volume>37</volume>: <fpage>137</fpage>–<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr38-0269216311419882">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Devas</surname><given-names>MB</given-names></name>
<name><surname>Dickson</surname><given-names>JW</given-names></name>
<name><surname>Jelliffe</surname><given-names>AM</given-names></name>
</person-group>. <article-title>Pathological fractures; treatment by internal fixation and irradiation</article-title>. <source>Lancet</source> <year>1956</year>; <volume>271</volume>: <fpage>484</fpage>–<lpage>487</lpage>.</citation>
</ref>
<ref id="bibr39-0269216311419882">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Heisterberg</surname><given-names>L</given-names></name>
<name><surname>Johansen</surname><given-names>TS</given-names></name>
</person-group>. <article-title>Treatment of pathological fractures</article-title>. <source>Acta Orthop Scand</source> <year>1979</year>; <volume>50</volume>: <fpage>787</fpage>–<lpage>790</lpage>.</citation>
</ref>
<ref id="bibr40-0269216311419882">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>RN</given-names></name>
<name><surname>Sherry</surname><given-names>HS</given-names></name>
<name><surname>Siffert</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Surgical management of metastatic disease of bone at the hip</article-title>. <source>Clin Orthop Relat Res</source> <year>1982</year>; <volume>169</volume>: <fpage>62</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr41-0269216311419882">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rock</surname><given-names>MG</given-names></name>
<name><surname>Harrington</surname><given-names>K</given-names></name>
</person-group>. <article-title>Pathologic fractures of the acetabulum and the pelvis</article-title>. <source>Orthopedics</source> <year>1992</year>; <volume>15</volume>: <fpage>569</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr42-0269216311419882">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zickel</surname><given-names>RE</given-names></name>
<name><surname>Mouradian</surname><given-names>WH</given-names></name>
</person-group>. <article-title>Intramedullary fixation of pathological fractures and lesions of the subtrochanteric region of the femur</article-title>. <source>J Bone Joint Surg Am</source> <year>1976</year>; <volume>58</volume>: <fpage>1061</fpage>–<lpage>1066</lpage>.</citation>
</ref>
<ref id="bibr43-0269216311419882">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mickelson</surname><given-names>MR</given-names></name>
<name><surname>Bonfiglio</surname><given-names>M</given-names></name>
</person-group>. <article-title>Pathological fractures in the proximal part of the femur treated by Zickel-nail fixation</article-title>. <source>J Bone Joint Surg Am</source> <year>1976</year>; <volume>58</volume>: <fpage>1067</fpage>–<lpage>1070</lpage>.</citation>
</ref>
<ref id="bibr44-0269216311419882">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Douglass</surname><given-names>HO</given-names><suffix>Jr.</suffix></name>
<name><surname>Shukla</surname><given-names>SK</given-names></name>
<name><surname>Mindell</surname><given-names>E</given-names></name>
</person-group>. <article-title>Treatment of pathological fractures of long bones excluding those due to breast cancer</article-title>. <source>J Bone Joint Surg Am</source> <year>1976</year>; <volume>58</volume>: <fpage>1055</fpage>–<lpage>1061</lpage>.</citation>
</ref>
<ref id="bibr45-0269216311419882">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dijkstra</surname><given-names>S</given-names></name>
<name><surname>Stapert</surname><given-names>J</given-names></name>
<name><surname>Boxma</surname><given-names>H</given-names></name>
<name><surname>Wiggers</surname><given-names>T</given-names></name>
</person-group>. <article-title>Treatment of pathological fractures of the humeral shaft due to bone metastases: a comparison of intramedullary locking nail and plate osteosynthesis with adjunctive bone cement</article-title>. <source>Eur J Surg Oncol</source> <year>1996</year>; <volume>22</volume>: <fpage>621</fpage>–<lpage>626</lpage>.</citation>
</ref>
<ref id="bibr46-0269216311419882">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dijkstra</surname><given-names>S</given-names></name>
<name><surname>Wiggers</surname><given-names>T</given-names></name>
<name><surname>van Geel</surname><given-names>BN</given-names></name>
<name><surname>Boxma</surname><given-names>H</given-names></name>
</person-group>. <article-title>Impending and actual pathological fractures in patients with bone metastases of the long bones. A retrospective study of 233 surgically treated fractures</article-title>. <source>Eur J Surg</source> <year>1994</year>; <volume>160</volume>: <fpage>535</fpage>–<lpage>542</lpage>.</citation>
</ref>
<ref id="bibr47-0269216311419882">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Perez</surname><given-names>CA</given-names></name>
<name><surname>Bradfield</surname><given-names>JS</given-names></name>
<name><surname>Morgan</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Management of pathologic fractures</article-title>. <source>Cancer</source> <year>1972</year>; <volume>29</volume>: <fpage>684</fpage>–<lpage>693</lpage>.</citation>
</ref>
<ref id="bibr48-0269216311419882">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tan</surname><given-names>JL</given-names></name>
<name><surname>Lo</surname><given-names>NN</given-names></name>
<name><surname>Tan</surname><given-names>SK</given-names></name>
</person-group>. <article-title>Surgical treatment of metastatic long bone disease</article-title>. <source>Singapore Med J</source> <year>1992</year>; <volume>33</volume>: <fpage>355</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr49-0269216311419882">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gebhart</surname><given-names>M</given-names></name>
<name><surname>Roman</surname><given-names>A</given-names></name>
<name><surname>Ghanem</surname><given-names>G</given-names></name>
<name><surname>Lejeune</surname><given-names>F</given-names></name>
</person-group>. <article-title>Surgical treatment of bone metastases of the peripheral skeleton–a review of 33 cases</article-title>. <source>Eur J Surg Oncol</source> <year>1989</year>; <volume>15</volume>: <fpage>520</fpage>–<lpage>529</lpage>.</citation>
</ref>
<ref id="bibr50-0269216311419882">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aboulafia</surname><given-names>AJ</given-names></name>
<name><surname>Buch</surname><given-names>R</given-names></name>
<name><surname>Mathews</surname><given-names>J</given-names></name>
<name><surname>Li</surname><given-names>W</given-names></name>
<name><surname>Malawer</surname><given-names>MM</given-names></name>
</person-group>. <article-title>Reconstruction using the saddle prosthesis following excision of primary and metastatic periacetabular tumors</article-title>. <source>Clin Orthop Relat Res</source> <year>1995</year>; <volume>314</volume>: <fpage>203</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr51-0269216311419882">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aboulafia</surname><given-names>AJ</given-names></name>
<name><surname>Malawer</surname><given-names>MM</given-names></name>
</person-group>. <article-title>Surgical management of pelvic and extremity osteosarcoma</article-title>. <source>Cancer</source> <year>1993</year>; <volume>71</volume> (<issue>10 Suppl</issue>): <fpage>3358</fpage>–<lpage>3366</lpage>.</citation>
</ref>
<ref id="bibr52-0269216311419882">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marco</surname><given-names>RA</given-names></name>
<name><surname>Sheth</surname><given-names>DS</given-names></name>
<name><surname>Boland</surname><given-names>PJ</given-names></name>
<name><surname>Wunder</surname><given-names>JS</given-names></name>
<name><surname>Siegel</surname><given-names>JA</given-names></name>
<name><surname>Healey</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Functional and oncological outcome of acetabular reconstruction for the treatment of metastatic disease</article-title>. <source>J Bone Joint Surg Am</source> <year>2000</year>; <volume>82</volume>: <fpage>642</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr53-0269216311419882">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haentjens</surname><given-names>P</given-names></name>
<name><surname>De Neve</surname><given-names>W</given-names></name>
<name><surname>Opdecam</surname><given-names>P</given-names></name>
</person-group>. <article-title>Prosthesis for the treatment of metastatic bone disease of the hip: effects of radiotherapy</article-title>. <source>Bull Cancer</source> <year>1995</year>; <volume>82</volume>: <fpage>961</fpage>–<lpage>970</lpage>.</citation>
</ref>
<ref id="bibr54-0269216311419882">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katzer</surname><given-names>A</given-names></name>
<name><surname>Meenen</surname><given-names>NM</given-names></name>
<name><surname>Grabbe</surname><given-names>F</given-names></name>
<name><surname>Rueger</surname><given-names>JM</given-names></name>
</person-group>. <article-title>Surgery of skeletal metastases</article-title>. <source>Arch Orthop Trauma Surg</source> <year>2002</year>; <volume>122</volume>: <fpage>251</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr55-0269216311419882">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gebhart</surname><given-names>M</given-names></name>
<name><surname>Guenier</surname><given-names>C</given-names></name>
<name><surname>Ghanem</surname><given-names>G</given-names></name>
<name><surname>Lejeune</surname><given-names>F</given-names></name>
</person-group>. <article-title>Surgical treatment of bony metastases of the peripheral skeleton: review of 87 cases</article-title>. <source>Acta Orthop Belg</source> <year>1993</year>; <volume>59</volume> (<issue>Suppl 1</issue>): <fpage>31</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr56-0269216311419882">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lane</surname><given-names>JM</given-names></name>
<name><surname>Sculco</surname><given-names>TP</given-names></name>
<name><surname>Zolan</surname><given-names>S</given-names></name>
</person-group>. <article-title>Treatment of pathological fractures of the hip by endoprosthetic replacement</article-title>. <source>J Bone Joint Surg Am</source> <year>1980</year>; <volume>62</volume>: <fpage>954</fpage>–<lpage>959</lpage>.</citation>
</ref>
<ref id="bibr57-0269216311419882">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Camnasio</surname><given-names>F</given-names></name>
<name><surname>Scotti</surname><given-names>C</given-names></name>
<name><surname>Peretti</surname><given-names>GM</given-names></name>
<name><surname>Fontana</surname><given-names>F</given-names></name>
<name><surname>Fraschini</surname><given-names>G</given-names></name>
</person-group>. <article-title>Prosthetic joint replacement for long bone metastases: analysis of 154 cases</article-title>. <source>Arch Orthop Trauma Surg</source> <year>2008</year>; <volume>128</volume>: <fpage>787</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr58-0269216311419882">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benevenia</surname><given-names>J</given-names></name>
<name><surname>Cyran</surname><given-names>FP</given-names></name>
<name><surname>Biermann</surname><given-names>JS</given-names></name>
<name><surname>Patterson</surname><given-names>FR</given-names></name>
<name><surname>Leeson</surname><given-names>MC</given-names></name>
</person-group>. <article-title>Treatment of advanced metastatic lesions of the acetabulum using the saddle prosthesis</article-title>. <source>Clin Orthop Relat Res</source> <year>2004</year>; <volume>426</volume>: <fpage>23</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr59-0269216311419882">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bickels</surname><given-names>J</given-names></name>
<name><surname>Kollender</surname><given-names>Y</given-names></name>
<name><surname>Wittig</surname><given-names>JC</given-names></name>
<name><surname>Meller</surname><given-names>I</given-names></name>
<name><surname>Malawer</surname><given-names>MM</given-names></name>
</person-group>. <article-title>Function after resection of humeral metastases: analysis of 59 consecutive patients</article-title>. <source>Clin Orthop Relat Res</source> <year>2005</year>; <volume>437</volume>: <fpage>201</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr60-0269216311419882">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Talbot</surname><given-names>M</given-names></name>
<name><surname>Turcotte</surname><given-names>RE</given-names></name>
<name><surname>Isler</surname><given-names>M</given-names></name>
<name><surname>Normandin</surname><given-names>D</given-names></name>
<name><surname>Iannuzzi</surname><given-names>D</given-names></name>
<name><surname>Downer</surname><given-names>P</given-names></name>
</person-group>. <article-title>Function and health status in surgically treated bone metastases</article-title>. <source>Clin Orthop Relat Res</source> <year>2005</year>; <volume>438</volume>: <fpage>215</fpage>–<lpage>220</lpage>.</citation>
</ref>
<ref id="bibr61-0269216311419882">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Park</surname><given-names>DH</given-names></name>
<name><surname>Jaiswal</surname><given-names>PK</given-names></name>
<name><surname>Al-Hakim</surname><given-names>W</given-names></name>
<name><surname>Aston</surname><given-names>WJ</given-names></name>
<name><surname>Pollock</surname><given-names>RC</given-names></name>
<name><surname>Skinner</surname><given-names>JA</given-names></name>
<etal/>
</person-group>. <article-title>The use of massive endoprostheses for the treatment of bone metastases</article-title>. <source>Sarcoma</source> <year>2007</year>; <volume>2007</volume>: <fpage>62151</fpage>.</citation>
</ref>
<ref id="bibr62-0269216311419882">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vena</surname><given-names>VE</given-names></name>
<name><surname>Hsu</surname><given-names>J</given-names></name>
<name><surname>Rosier</surname><given-names>RN</given-names></name>
<name><surname>O’Keefe</surname><given-names>RJ</given-names></name>
</person-group>. <article-title>Pelvic reconstruction for severe periacetabular metastatic disease</article-title>. <source>Clin Orthop Relat Res</source> <year>1999</year>; <volume>362</volume>: <fpage>171</fpage>–<lpage>180</lpage>.</citation>
</ref>
<ref id="bibr63-0269216311419882">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ofluoglu</surname><given-names>O</given-names></name>
<name><surname>Erol</surname><given-names>B</given-names></name>
<name><surname>Ozgen</surname><given-names>Z</given-names></name>
<name><surname>Yildiz</surname><given-names>M</given-names></name>
</person-group>. <article-title>Minimally invasive treatment of pathological fractures of the humeral shaft</article-title>. <source>Int Orthop</source> <year>2008</year>; <volume>33</volume>: <fpage>707</fpage>–<lpage>712</lpage>.</citation>
</ref>
<ref id="bibr64-0269216311419882">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Allan</surname><given-names>DG</given-names></name>
<name><surname>Bell</surname><given-names>RS</given-names></name>
<name><surname>Davis</surname><given-names>A</given-names></name>
<name><surname>Langer</surname><given-names>F</given-names></name>
</person-group>. <article-title>Complex acetabular reconstruction for metastatic tumor</article-title>. <source>J Arthroplasty</source> <year>1995</year>; <volume>10</volume>: <fpage>301</fpage>–<lpage>306</lpage>.</citation>
</ref>
<ref id="bibr65-0269216311419882">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacAusland</surname><given-names>WR</given-names><suffix>Jr.</suffix></name>
<name><surname>Wyman</surname><given-names>ET</given-names><suffix>Jr.</suffix></name>
</person-group> <article-title>Management of metastatic pathological fractures</article-title>. <source>Clin Orthop Relat Res</source> <year>1970</year>; <volume>73</volume>: <fpage>39</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr66-0269216311419882">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cheng</surname><given-names>EY</given-names></name>
</person-group>. <article-title>Prospective quality of life research in bony metastatic disease</article-title>. <source>Clin Orthop Relat Res</source> <year>2003</year>; <volume>415</volume> <supplement>Suppl</supplement>: <fpage>S289</fpage>–<lpage>S297</lpage>.</citation>
</ref>
<ref id="bibr67-0269216311419882">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sorensen</surname><given-names>JB</given-names></name>
<name><surname>Klee</surname><given-names>M</given-names></name>
<name><surname>Palshof</surname><given-names>T</given-names></name>
<name><surname>Hansen</surname><given-names>HH</given-names></name>
</person-group>. <article-title>Performance status assessment in cancer patients. An inter-observer variability study</article-title>. <source>Br J Cancer</source> <year>1993</year>; <volume>67</volume>: <fpage>773</fpage>–<lpage>775</lpage>.</citation>
</ref>
<ref id="bibr68-0269216311419882">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Orr</surname><given-names>ST</given-names></name>
<name><surname>Aisner</surname><given-names>J</given-names></name>
</person-group>. <article-title>Performance status assessment among oncology patients: a review</article-title>. <source>Cancer Treat Rep</source> <year>1986</year>; <volume>70</volume>: <fpage>1423</fpage>–<lpage>1429</lpage>.</citation>
</ref>
<ref id="bibr69-0269216311419882">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Conill</surname><given-names>C</given-names></name>
<name><surname>Verger</surname><given-names>E</given-names></name>
<name><surname>Salamero</surname><given-names>M</given-names></name>
</person-group>. <article-title>Performance status assessment in cancer patients</article-title>. <source>Cancer</source> <year>1990</year>; <volume>65</volume>: <fpage>1864</fpage>–<lpage>1866</lpage>.</citation>
</ref>
<ref id="bibr70-0269216311419882">
<label>70.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katagiri</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>M</given-names></name>
<name><surname>Wakai</surname><given-names>K</given-names></name>
<name><surname>Sugiura</surname><given-names>H</given-names></name>
<name><surname>Kataoka</surname><given-names>T</given-names></name>
<name><surname>Nakanishi</surname><given-names>K</given-names></name>
</person-group>. <article-title>Prognostic factors and a scoring system for patients with skeletal metastasis</article-title>. <source>J Bone Joint Surg Br</source> <year>2005</year>; <volume>87</volume>: <fpage>698</fpage>–<lpage>703</lpage>.</citation>
</ref>
<ref id="bibr71-0269216311419882">
<label>71.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Karnofsky</surname><given-names>DA</given-names></name>
<name><surname>Burchenal</surname><given-names>JH</given-names></name>
</person-group>. <article-title>The clinical evaluation of chemotherapeutic agents in cancer</article-title>. In: <person-group person-group-type="editor">
<name><surname>MacLeod</surname><given-names>CM</given-names></name>
</person-group> (ed.) <source>Evaluation of chemotherapeutic agents</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Columbia University Press</publisher-name>, <year>1949</year>, p.<fpage>196</fpage>.</citation>
</ref>
<ref id="bibr72-0269216311419882">
<label>72.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schag</surname><given-names>CC</given-names></name>
<name><surname>Heinrich</surname><given-names>RL</given-names></name>
<name><surname>Ganz</surname><given-names>PA</given-names></name>
</person-group>. <article-title>Karnofsky performance status revisited: reliability, validity, and guidelines</article-title>. <source>J Clin Oncol</source> <year>1984</year>; <volume>2</volume>: <fpage>187</fpage>–<lpage>193</lpage>.</citation>
</ref>
<ref id="bibr73-0269216311419882">
<label>73.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giurea</surname><given-names>A</given-names></name>
<name><surname>Ritschl</surname><given-names>P</given-names></name>
<name><surname>Windhager</surname><given-names>R</given-names></name>
<name><surname>Kaider</surname><given-names>A</given-names></name>
<name><surname>Helwig</surname><given-names>U</given-names></name>
<name><surname>Kotz</surname><given-names>R</given-names></name>
</person-group>. <article-title>The benefits of surgery in the treatment of pelvic metastases</article-title>. <source>Int Orthop</source> <year>1997</year>; <volume>21</volume>: <fpage>343</fpage>–<lpage>348</lpage>.</citation>
</ref>
<ref id="bibr74-0269216311419882">
<label>74.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hansen</surname><given-names>BH</given-names></name>
<name><surname>Keller</surname><given-names>J</given-names></name>
<name><surname>Laitinen</surname><given-names>M</given-names></name>
<name><surname>Berg</surname><given-names>P</given-names></name>
<name><surname>Skjeldal</surname><given-names>S</given-names></name>
<name><surname>Trovik</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>The Scandinavian Sarcoma Group Skeletal Metastasis Register. Survival after surgery for bone metastases in the pelvis and extremities</article-title>. <source>Acta Orthop Scand Suppl</source> <year>2004</year>; <volume>75</volume>: <fpage>11</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr75-0269216311419882">
<label>75.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wedin</surname><given-names>R</given-names></name>
<name><surname>Bauer</surname><given-names>HC</given-names></name>
</person-group>. <article-title>Surgical treatment of skeletal metastatic lesions of the proximal femur: endoprosthesis or reconstruction nail?</article-title> <source>J Bone Joint Surg Br</source> <year>2005</year>; <volume>87</volume>: <fpage>1653</fpage>–<lpage>1657</lpage>.</citation>
</ref>
<ref id="bibr76-0269216311419882">
<label>76.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hardman</surname><given-names>PD</given-names></name>
<name><surname>Robb</surname><given-names>JE</given-names></name>
<name><surname>Kerr</surname><given-names>GR</given-names></name>
<name><surname>Rodger</surname><given-names>A</given-names></name>
<name><surname>MacFarlane</surname><given-names>A</given-names></name>
</person-group>. <article-title>The value of internal fixation and radiotherapy in the management of upper and lower limb bone metastases</article-title>. <source>Clin Oncol (R Coll Radiol)</source> <year>1992</year>; <volume>4</volume>: <fpage>244</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr77-0269216311419882">
<label>77.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gristina</surname><given-names>AG</given-names></name>
<name><surname>Adair</surname><given-names>DM</given-names></name>
<name><surname>Spurr</surname><given-names>CL</given-names></name>
</person-group>. <article-title>Intraosseous metastatic breast cancer treatment with internal fixation and study of survival</article-title>. <source>Ann Surg</source> <year>1983</year>; <volume>197</volume>: <fpage>128</fpage>–<lpage>134</lpage>.</citation>
</ref>
<ref id="bibr78-0269216311419882">
<label>78.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Enneking</surname><given-names>WF</given-names></name>
<name><surname>Dunham</surname><given-names>W</given-names></name>
<name><surname>Gebhardt</surname><given-names>MC</given-names></name>
<name><surname>Malawar</surname><given-names>M</given-names></name>
<name><surname>Pritchard</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system</article-title>. <source>Clin Orthop Relat Res</source> <year>1993</year>; <volume>286</volume>: <fpage>241</fpage>–<lpage>246</lpage>.</citation>
</ref>
<ref id="bibr79-0269216311419882">
<label>79.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>AM</given-names></name>
<name><surname>Bell</surname><given-names>RS</given-names></name>
<name><surname>Badley</surname><given-names>EM</given-names></name>
<name><surname>Yoshida</surname><given-names>K</given-names></name>
<name><surname>Williams</surname><given-names>JI</given-names></name>
</person-group>. <article-title>Evaluating functional outcome in patients with lower extremity sarcoma</article-title>. <source>Clin Orthop Relat Res</source> <year>1999</year>; <volume>358</volume>: <fpage>90</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr80-0269216311419882">
<label>80.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Davis</surname><given-names>AM</given-names></name>
<name><surname>Wright</surname><given-names>JG</given-names></name>
<name><surname>Williams</surname><given-names>JI</given-names></name>
<name><surname>Bombardier</surname><given-names>C</given-names></name>
<name><surname>Griffin</surname><given-names>A</given-names></name>
<name><surname>Bell</surname><given-names>RS</given-names></name>
</person-group>. <article-title>Development of a measure of physical function for patients with bone and soft tissue sarcoma</article-title>. <source>Qual Life Res</source> <year>1996</year>; <volume>5</volume>: <fpage>508</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr81-0269216311419882">
<label>81.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sim</surname><given-names>FH</given-names></name>
<name><surname>Daugherty</surname><given-names>TW</given-names></name>
<name><surname>Ivins</surname><given-names>JC</given-names></name>
</person-group>. <article-title>The adjunctive use of methylmethacrylate in fixation of pathological fractures</article-title>. <source>J Bone Joint Surg Am</source> <year>1974</year>; <volume>56</volume>: <fpage>40</fpage>–<lpage>48</lpage>.</citation>
</ref>
<ref id="bibr82-0269216311419882">
<label>82.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauer</surname><given-names>HC</given-names></name>
<name><surname>Wedin</surname><given-names>R</given-names></name>
</person-group>. <article-title>Survival after surgery for spinal and extremity metastases. Prognostication in 241 patients</article-title>. <source>Acta Orthop Scand</source> <year>1995</year>; <volume>66</volume>: <fpage>143</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr83-0269216311419882">
<label>83.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Durr</surname><given-names>HR</given-names></name>
<name><surname>Muller</surname><given-names>PE</given-names></name>
<name><surname>Lenz</surname><given-names>T</given-names></name>
<name><surname>Baur</surname><given-names>A</given-names></name>
<name><surname>Jansson</surname><given-names>V</given-names></name>
<name><surname>Refior</surname><given-names>HJ</given-names></name>
</person-group>. <article-title>Surgical treatment of bone metastases in patients with breast cancer</article-title>. <source>Clin Orthop Relat Res</source> <year>2002</year>; <volume>396</volume>: <fpage>191</fpage>–<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr84-0269216311419882">
<label>84.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Durr</surname><given-names>HR</given-names></name>
<name><surname>Maier</surname><given-names>M</given-names></name>
<name><surname>Pfahler</surname><given-names>M</given-names></name>
<name><surname>Baur</surname><given-names>A</given-names></name>
<name><surname>Refior</surname><given-names>HJ</given-names></name>
</person-group>. <article-title>Surgical treatment of osseous metastases in patients with renal cell carcinoma</article-title>. <source>Clin Orthop Relat Res</source> <year>1999</year>; <volume>367</volume>: <fpage>283</fpage>–<lpage>290</lpage>.</citation>
</ref>
<ref id="bibr85-0269216311419882">
<label>85.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Townsend</surname><given-names>PW</given-names></name>
<name><surname>Smalley</surname><given-names>SR</given-names></name>
<name><surname>Cozad</surname><given-names>SC</given-names></name>
<name><surname>Rosenthal</surname><given-names>HG</given-names></name>
<name><surname>Hassanein</surname><given-names>RE</given-names></name>
</person-group>. <article-title>Role of postoperative radiation therapy after stabilization of fractures caused by metastatic disease</article-title>. <source>Int J Radiat Oncol Biol Phys</source> <year>1995</year>; <volume>31</volume>: <fpage>43</fpage>–<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr86-0269216311419882">
<label>86.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wedin</surname><given-names>R</given-names></name>
</person-group>. <article-title>Surgical treatment for pathologic fracture</article-title>. <source>Acta Orthop Scand Suppl</source> <year>2001</year>; <volume>72</volume>: <fpage>1</fpage>–<lpage>29</lpage>.</citation>
</ref>
<ref id="bibr87-0269216311419882">
<label>87.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Stoll</surname><given-names>BA</given-names></name>
</person-group>. <article-title>Natural history, prognosis and staging of bone metastasis</article-title>. In: <person-group person-group-type="editor">
<name><surname>Stoll</surname><given-names>BA</given-names></name>
<name><surname>Parbhoo</surname><given-names>S</given-names></name>
</person-group> (ed.) <source>Bone metastasis: monitoring and treatment</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Raven Press</publisher-name>, <year>1983</year>, pp.<fpage>1</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr88-0269216311419882">
<label>88.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tokuhashi</surname><given-names>Y</given-names></name>
<name><surname>Matsuzaki</surname><given-names>H</given-names></name>
<name><surname>Toriyama</surname><given-names>S</given-names></name>
<name><surname>Kawano</surname><given-names>H</given-names></name>
<name><surname>Ohsaka</surname><given-names>S</given-names></name>
</person-group>. <article-title>Scoring system for the preoperative evaluation of metastatic spine tumor prognosis</article-title>. <source>Spine</source> <year>1990</year>; <volume>15</volume>: <fpage>1110</fpage>–<lpage>1113</lpage>.</citation>
</ref>
<ref id="bibr89-0269216311419882">
<label>89.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Damron</surname><given-names>TA</given-names></name>
<name><surname>Ward</surname><given-names>WG</given-names></name>
</person-group>. <article-title>Risk of pathologic fracture: assessment</article-title>. <source>Clin Orthop Relat Res</source> <year>2003</year>; <volume>415</volume> <issue>Suppl</issue>: <fpage>S208</fpage>–<lpage>S211</lpage>.</citation>
</ref>
<ref id="bibr90-0269216311419882">
<label>90.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harrington</surname><given-names>KD</given-names></name>
</person-group>. <article-title>Impending pathologic fractures from metastatic malignancy: evaluation and management</article-title>. <source>Instr Course Lect</source> <year>1986</year>; <volume>35</volume>: <fpage>357</fpage>–<lpage>381</lpage>.</citation>
</ref>
<ref id="bibr91-0269216311419882">
<label>91.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aaron</surname><given-names>AD</given-names></name>
</person-group>. <article-title>The management of cancer metastatic to bone</article-title>. <source>J Am Med Assoc</source> <year>1994</year>; <volume>272</volume>: <fpage>1206</fpage>–<lpage>1209</lpage>.</citation>
</ref>
<ref id="bibr92-0269216311419882">
<label>92.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Damron</surname><given-names>TA</given-names></name>
<name><surname>Morgan</surname><given-names>H</given-names></name>
<name><surname>Prakash</surname><given-names>D</given-names></name>
<name><surname>Grant</surname><given-names>W</given-names></name>
<name><surname>Aronowitz</surname><given-names>J</given-names></name>
<name><surname>Heiner</surname><given-names>J</given-names></name>
</person-group>. <article-title>Critical evaluation of Mirels’ rating system for impending pathologic fractures</article-title>. <source>Clin Orthop Relat Res</source> <year>2003</year>; <volume>415</volume> <issue>Suppl</issue>: <fpage>S201</fpage>–<lpage>S207</lpage>.</citation>
</ref>
<ref id="bibr93-0269216311419882">
<label>93.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beals</surname><given-names>RK</given-names></name>
<name><surname>Lawton</surname><given-names>GD</given-names></name>
<name><surname>Snell</surname><given-names>WE</given-names></name>
</person-group>. <article-title>Prophylactic internal fixation of the femur in metastatic breast cancer</article-title>. <source>Cancer</source> <year>1971</year>; <volume>28</volume>: <fpage>1350</fpage>–<lpage>1354</lpage>.</citation>
</ref>
<ref id="bibr94-0269216311419882">
<label>94.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bono</surname><given-names>B</given-names></name>
<name><surname>Cazzaniga</surname><given-names>P</given-names></name>
<name><surname>Pini</surname><given-names>V</given-names></name>
<name><surname>Zurrida</surname><given-names>SM</given-names></name>
<name><surname>Spagnolo</surname><given-names>R</given-names></name>
<name><surname>Torelli</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Palliative surgery of metastatic bone disease: a review of 83 cases</article-title>. <source>Eur J Cancer</source> <year>1991</year>; <volume>27</volume>: <fpage>556</fpage>–<lpage>558</lpage>.</citation>
</ref>
<ref id="bibr95-0269216311419882">
<label>95.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Capanna</surname><given-names>R</given-names></name>
<name><surname>De Biase</surname><given-names>P</given-names></name>
<name><surname>Campanacci</surname><given-names>DA</given-names></name>
</person-group>. <article-title>A new protocol of surgical treatment of long bone metastases</article-title>. <source>Ortop Traumatol Rehabil</source> <year>2003</year>; <volume>5</volume>: <fpage>271</fpage>–<lpage>275</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>